IP Library Granted Patent US 9,655,945
Granted Patent B2
US 9,655,945 · App. 15/198,050 · Granted May 23, 2017

Treatment of ascites

Inventors: Paolo Angeli (Padua, IT); Penelope Markham (Clifton, VA); Jonathan Adams (Chicago, IL)
Assignee: BIOVIE, Inc.
A61K38/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,945
App. No.
15/198,050
Granted
May 23, 2017
Kind
B2
Abstract

A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.

Claims (14)

1. A method for treating a patient diagnosed with ascites due to liver cirrhosis, the method comprising administering terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day to the patient for about one day to about 12 months.

2. The method of claim 1 , wherein the continuous terlipressin is administered for about one day to about six months.

3. The method of claim 1 , wherein the continuous terlipressin is administered with an ambulatory infusion pump.

4. The method of claim 1 , wherein the patient has not progressed to hepatorenal syndrome (HRS).

5. The method of claim 1 , wherein the administration of terlipressin is provided on an out-patient basis.

6. The method of claim 1 , wherein the administered dose of terlipressin escalates over the about one day to about 12 months.

7. A method for reducing the accumulation of ascitic fluid in the abdominal cavity in an ambulatory ascites patient, the method comprising administering to the patient terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day for about one day to about twelve months with an ambulatory infusion pump.

8. The method of claim 7 , wherein the terlipressin is administered for about one day to about six months.

9. The method of claim 7 , wherein the patient has not progressed to hepatorenal syndrome (HRS).

10. The method of claim 7 , wherein the administration is provided on an out-patient basis.

11. The method of claim 7 , wherein the administered dose of terlipressin escalates over the about one day to about 12 months.

12. The method of claim 1 , wherein patient has not progressed to FIRS type 1.

13. The method of claim 12 , where the patient is not hospitalized.

14. The method of claim 7 , wherein the patient has not progressed to HRS type 1.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2019
From: ANGELI, PAOLO
To: UNIVERSITA DEGLI STUDI DI PADOVA
Reel/Frame 049307/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2019
From: MARKHAM, PENELOPE; ADAMS, JONATHAN
To: BIOVIE INC.
Reel/Frame 049307/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: ANGELI, PAOLO
To: UNIVERSITA DEGLI STUDI DI PADOVA
Reel/Frame 040803/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: MARKHAM, PENELOPE; ADAMS, JONATHAN
To: NANOANTIBIOTICS, INC.
Reel/Frame 040803/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: UNIVERSITY OF PADOVA A/KA UNIVERSITA DEGLI STUDI DI PADOVA
To: BIOVIE INC.
Reel/Frame 040803/0500 →
CHANGE OF NAME Recorded Dec 29, 2016
From: NANOANTIBIOTICS, INC.
To: BIOVIE INC.
Reel/Frame 041212/0784 →
Continuity (4)
Provisional Application 62186638 · Jun 30, 2015
Provisional Application 62267510 · Dec 15, 2015
Provisional Application 62321558 · Apr 12, 2016
Related Publication 20170000844A1 · Jan 5, 2017